Moderate to Severe Plaque Psoriasis Efficacy Data | TREMFYA® (guselkumab) HCP

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

OTHER EFFICACY ENDPOINTS

Therapeutic Longevity: Nearly 9 Out of 10 Patients Who Achieved PASI 90 at Week 28 With TREMFYA® Maintained This Response at Week 48 With a Consistent Response Rate at Week 721*

View Study Design

VOYAGE 2: PRESPECIFIED EXPLORATORY ENDPOINT—MAINTENANCE AND DURABILITY OF PASI 90 RESPONSE1-3

maintenace-durability

Maintenance and durability of PASI 90 response at Weeks 48 and 72 were prespecified exploratory endpoints that were not adjusted for multiplicity; P values were considered nominal.

  • Major Secondary Endpoint: Median time to loss of PASI 90 response was 15 weeks (23 weeks after last TREMFYA® dose) for patients at Week 28 who were re-randomized to placebo and withdrawn from TREMFYA®

Based on the results of an analysis of the 115 global sites from VOYAGE 2 (including North American sites [ie, United States and Canada]).

The same patients may not have responded at each time point.

*Patients randomized to TREMFYA® at Week 0 who were PASI 90 responders at Week 28 were re-randomized to either continue treatment with TREMFYA® q8w (maintenance group) or receive placebo (withdrawal group).

Reference: 1. Data on file. Janssen Biotech, Inc.

TREMFYA® EFFICACY DATA IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS

Teaser: